US 5,665,777 AGranted

Biphenyl hydroxamate inhibitors of matrix metalloproteinases

AssigneeAbbott Laboratories

InventorsStephen W. Fesik, James B. Summers, Jr., Steven K. Davidsen, George S. Sheppard, Douglas H. Steinman, George M. Carrera, Jr., Alan Florjancic, James H. Holms

Life of this patent

Estimating the term…

Abstract

Compounds of formula ##STR1## or a pharmaceutically acceptable salt thereof inhibit matrix metalloproteinases and TNF.alpha. secretion and are useful in the treatment of inflammatory disease states. Also disclosed are matrix metalloproteinases and TNF.alpha. secretion inhibiting compositions and a method for inhibiting matrix metalloproteinases and TNF.alpha. secretion.

Claims14

Dependent claims

A compound of formula ##STR12## or a pharmaceutically acceptable salt thereof where m and n are independently 0 or 1;

p is 0-6, with the proviso that m, n, and p cannot simultaneously be zero;
R.sup.1 is selected from the group consisting of
(a) hydrogen;
(b) alkyl of one to six carbon atoms;
(c) (alkylene) of two to six carbon atoms;
(d) hydroxy;
(e) ##STR13## where the alkylene portion is of one to six carbon atoms, and R.sup.6 is selected from the group consisting of alkyl of one to six carbon atoms, haloalkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, and hydroxy;
(f) ##STR14## wherein q is 0, 1 or 2, the alkylene portion is of one to six carbon atoms, and R.sup.6 is defined above;
(g) -(alkylene)-CO.sub.2 R.sup.7 wherein the alkylene portion is of one to six carbon atoms, and R.sup.7 is hydrogen or alkyl of one to six carbon atoms;
R.sup.2 and R.sup.3 are independently selected from the group consisting of
(a) hydrogen;
(b) alkyl of one to six carbon atoms;
(c) phenyl;
(d) phenyl substituted with
halogen,
alkyl of one to six carbon atoms,
haloalkyl of one to six carbon atoms,
alkoxy of one to six carbon atoms, or
hydroxy;
(e) pyridyl, and
(f) pyridyl substituted with
halogen,
alkyl of one to six carbon atoms,
haloalkyl of one to six carbon atoms, or
alkoxy of one to six carbon atoms;
or
R.sup.2 and R.sup.3 taken together with the nitrogen atom to which they are attached define a 5- or 6-membered saturated heterocyclic ring in which the heterocyclic ring optionally contains an additional heteroatom selected from the group consisting of --NR.sup.8 wherein R.sup.8 is hydrogen or alkyl of one to six carbon atoms, --O--, --S--, or --S(O).sub.r -- wherein r is 1 or 2;
X is absent or is selected from the group consisting of
(a) --O--;
(b) --NH--;
and
(c) --S--;
with the provisos that
(a) when X is oxygen, and m and n are zero, p is an integer of two to six, inclusive, and
(b) when X is oxygen and m is one and n is zero;
then p is an integer of one to six, inclusive;
R.sup.4 and R.sup.5 are independently selected from the group consisting of
(a) hydrogen;
(b) alkyl of one to six carbon atoms;
(c) halogen;
(d) cyano;
(e) cyanoalkyl of one to six carbon atoms;
(f) haloalkyl of one to six carbon atoms,
(g) hydroxy, and
(h) alkoxy of one to six carbon atoms.

42 more elements

A compound or pharmaceutically acceptable salt thereof selected from the group consisting of

4-(4-phenylphenoxy)butanohydroxamic acid,
4-(3-phenylphenoxy)butanohydroxamic acid,
4-[4-(4-cyanophenyl)phenoxy]butanohydroxamic acid,
4-[4-(3-cyanophenyl)phenoxy]butanohydroxamic acid,
4-[4-(4-cyanomethylphenyl)phenoxy]butanohydroxamic acid,
4-[4-(3-cyanomethylphenyl)phenoxy]butanohydroxamic acid,
4-[4-(4-chlorophenyl)phenoxy]butanohydroxamic acid,
4-[4-(4-propylphenyl)phenoxy]butanohydroxamic acid,
4-[4-(4-methoxyphenyl)phenoxy]butanohydroxamic acid,
7-(4-phenylphenoxy)heptanohydroxamic acid,
7-[4-(4-cyanophenyl)phenoxy]heptanohydroxamic acid,
5-[3-(4-fluorophenyl)phenoxy]pentanohydroxamic acid,
5-[3-(3-cyanophenyl)phenoxyl]pentanohydroxamic acid,
5-[3-(4-cyanophenyl)phenoxy]pentanohydroxamic acid,
4-[3-(4-fluorophenyl)phenoxy]butanohydroxamic acid,
4-[3-(4-cyanophenyl)phenoxy]butanohydroxamic acid,
4-[3-(3-cyanophenyl)phenoxy]butanohydroxamic acid,
5-[3-phenylphenoxy]pentanohydroxamic acid,
5-[4-phenylphenoxy]pentanohydroxamic acid,
5-[4-(4-cyanophenyl)phenoxy]pentanohydroxamic acid,
6-[4-phenylphenoxy]hexanohydroxamic acid,
6-[4-(4-cyanophenyl)phenoxyl]hexanohydroxamic acid,
3-(4-phenylphenoxy)propanohydroxamic acid,
3-(3-phenylphenoxy)propanohydroxamic acid,
3-[4-(4-cyanophenyl)phenoxy]propanohydroxamic acid,
3-[4-(4-methoxyphenyl)phenoxy]propanohydroxamic acid,
3-[4-(4-fluorophenyl)phenoxy]propanohydroxamic acid,
(S)2-methyl-3-(4-phenylphenoxy)propanohydroxamic acid,
3-(N-methylcarboxamido)-5-[4-(4-cyanophenyl)phenoxy]pentanohydroxamic acid,
3-(4-biphenylthio)propanohydroxamic acid,
2-(4-biphenylthio)ethanohydroxamic acid,
3-(4-biphenylamino)propanohydroxamic acid,
2-(4-biphenyl)ethanohydroxamic acid,
4-(4-biphenyl)butanohydroxamic acid,
4-[4-(4-cyanophenyl)phenyl]butanohydroxamic acid,
3-(4-biphenyl)propanohydroxamic acid,
5-(4-biphenyl)pentanohydroxamic acid,
5-[4-(4-fluorophenyl)phenoxy]pentanohydroxamic acid,
4-(2-hydroxy-4-phenylphenoxy)butanohydroxamic acid,
4-(2-hydroxy-5-phenylphenoxy)butanohydroxamic acid,
3-[4-(3-cyanomethylphenyl)phenoxy]propanohydroxamic acid,
2-tert-butyloxycarbonylmethyl-4-[4-(4-cyanophenyl)phenoxy]butanohydroxamic acid,
3-[4-(4-cyanomethylphenyl)phenoxy]propanohydroxamic acid, and
2-hydroxy-3-[(4-phenyl)phenoxy]propanohydroxamic acid.

41 more elements

Dependencies are inferred from the claim text.

patentgrep

Loading patent…

Abstract

A compound of formula ##STR12## or a pharmaceutically acceptable salt thereof where m and n are independently 0 or 1;

p is 0-6, with the proviso that m, n, and p cannot simultaneously be zero;
R.sup.1 is selected from the group consisting of
(a) hydrogen;
(b) alkyl of one to six carbon atoms;
(c) (alkylene) of two to six carbon atoms;
(d) hydroxy;
(e) ##STR13## where the alkylene portion is of one to six carbon atoms, and R.sup.6 is selected from the group consisting of alkyl of one to six carbon atoms, haloalkyl of one to six carbon atoms, alkoxy of one to six carbon atoms, and hydroxy;
(f) ##STR14## wherein q is 0, 1 or 2, the alkylene portion is of one to six carbon atoms, and R.sup.6 is defined above;
(g) -(alkylene)-CO.sub.2 R.sup.7 wherein the alkylene portion is of one to six carbon atoms, and R.sup.7 is hydrogen or alkyl of one to six carbon atoms;
R.sup.2 and R.sup.3 are independently selected from the group consisting of
(a) hydrogen;
(b) alkyl of one to six carbon atoms;
(c) phenyl;
(d) phenyl substituted with
halogen,
alkyl of one to six carbon atoms,
haloalkyl of one to six carbon atoms,
alkoxy of one to six carbon atoms, or
hydroxy;
(e) pyridyl, and
(f) pyridyl substituted with
halogen,
alkyl of one to six carbon atoms,
haloalkyl of one to six carbon atoms, or
alkoxy of one to six carbon atoms;
or
R.sup.2 and R.sup.3 taken together with the nitrogen atom to which they are attached define a 5- or 6-membered saturated heterocyclic ring in which the heterocyclic ring optionally contains an additional heteroatom selected from the group consisting of --NR.sup.8 wherein R.sup.8 is hydrogen or alkyl of one to six carbon atoms, --O--, --S--, or --S(O).sub.r -- wherein r is 1 or 2;
X is absent or is selected from the group consisting of
(a) --O--;
(b) --NH--;
and
(c) --S--;
with the provisos that
(a) when X is oxygen, and m and n are zero, p is an integer of two to six, inclusive, and
(b) when X is oxygen and m is one and n is zero;
then p is an integer of one to six, inclusive;
R.sup.4 and R.sup.5 are independently selected from the group consisting of
(a) hydrogen;
(b) alkyl of one to six carbon atoms;
(c) halogen;
(d) cyano;
(e) cyanoalkyl of one to six carbon atoms;
(f) haloalkyl of one to six carbon atoms,
(g) hydroxy, and
(h) alkoxy of one to six carbon atoms.

42 more elements